Medivir, Financial Statement, 1 January - 31 December 2008

Medivir, Financial Statement, 1 January - 31 December 2008

•  Net sales were SEK 97.2 (249.6) m. In May, Medivir signed another agreement
with Tibotec Pharmaceuticals Ltd. regarding hepatitis C, triggering a EUR 5 m
payment. A milestone payment of EUR 2.6 m was received in December when a CD
(candidate drug) was designated.
•  The loss after tax was SEK -99.2 (-29.3) m.
•  Earnings per share were SEK -4.76 (-1.74).
•  Cash flow from operating activities was SEK -34.8 (-70.5) m.
•  Liquid assets as of 31 December were SEK 284.4 (329.3) m.
•  Ron Long appointed as CEO.

Fourth quarter in brief

Several significant project events were reported in the quarter: Clinical data
and milestone payments on our hepatitis C projects, in tandem with continued
work on Lipsovir's® NDA. In December, Medivir reported that Lars Adlersson would
be leaving the company after six years as CEO.

The highlights can be summarized as follows:
•  Positive phase IIa data from the first two dose groups for TMC435 against
hepatitis C was presented at the Annual Meeting of the AASLD (American
Association for the Study of Liver Diseases) in early November.
•  An NDA for Lipsovir® was filed with the US (FDA) and European regulatory
authorities.
•  Milestone payment of EUR 2.6 m on designation of a CD in the hepatitis C
collaboration with Tibotec in the polymerase segment.

Ron Long 
CEO

Huddinge, Sweden, 19 February 2008


FORTHCOMING FINANCIAL INFORMATION
The Three-month Interim Report will be published on 23 April 2009.
The AGM will be held at 3pm on 23 April 2009.
The Six-month Interim Report will be published on 9 July 2009.
The Nine-month Interim Report will be published on 21 October 2009.

The Report will be available at Medivir's Website, www.medivir.se from this date
under the ‘Investor/Media' heading.

For more information, please contact:
Rein Piir, CFO and VP, Investor Relations: +46 (0)70 853 7292 or +46 (0)8 546
83123.